JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB185703

Anti-TIM 3 antibody

4

(5 Reviews)

|

(43 Publications)

Rabbit Polyclonal TIM 3 antibody. Suitable for WB and reacts with Mouse, Rat, Human samples. Cited in 43 publications. Immunogen corresponding to Recombinant Fragment Protein within Human HAVCR2 aa 1-250.

View Alternative Names

CD366, TIM3, TIMD3, HAVCR2, Hepatitis A virus cellular receptor 2, HAVcr-2, T-cell immunoglobulin and mucin domain-containing protein 3, T-cell immunoglobulin mucin receptor 3, T-cell membrane protein 3, TIMD-3, TIM-3

2 Images
Western blot - Anti-TIM 3 antibody (AB185703)
  • WB

Supplier Data

Western blot - Anti-TIM 3 antibody (AB185703)

All lanes:

Western blot - Anti-TIM 3 antibody (ab185703) at 1/1000 dilution

Lane 1:

HepG2 cell lysate at 25 µg

Lane 2:

BxPC-3 cell lysate at 25 µg

Lane 3:

BT-474 cell lysate at 25 µg

Lane 4:

U-937 cell lysate at 25 µg

Lane 5:

Mouse lung tissue lysate at 25 µg

Lane 6:

Mouse thymus tissue lysate at 25 µg

Secondary

All lanes:

HRP Goat Anti-Rabbit IgG

Predicted band size: 33 kDa

true

Exposure time: 10s

Western blot - Anti-TIM 3 antibody (AB185703)
  • WB

Supplier Data

Western blot - Anti-TIM 3 antibody (AB185703)

All lanes:

Western blot - Anti-TIM 3 antibody (ab185703) at 1/1000 dilution

Lane 1:

HepG2 cell lysate at 25 µg

Lane 2:

A-549 cell lysate at 25 µg

Lane 3:

THP-1 cell lysate at 25 µg

Lane 4:

Mouse spleen tissue lysate at 25 µg

Lane 5:

Mouse lung tissue lysate at 25 µg

Lane 6:

Mouse thymus tissue lysate at 25 µg

Lane 7:

Rat spleen tissue lysate at 25 µg

Secondary

All lanes:

HRP Goat Anti-Rabbit IgG

Predicted band size: 33 kDa

true

Exposure time: 30s

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Mouse, Rat, Human

Applications

WB

applications

Immunogen

Recombinant Fragment Protein within Human HAVCR2 aa 1-250. The exact immunogen used to generate this antibody is proprietary information.

Q8TDQ0

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/2000", "WB-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>" }, "Rat": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7.3 Preservative: 0.09% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine)
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TIM-3 also known as T cell immunoglobulin and mucin-domain containing-3 or HAVCR2 is a protein involved in immune regulation. It possesses an approximate mass of 35 kDa. TIM-3 is expressed on various immune cells including T cells NK cells and dendritic cells especially after activation. The expression level often changes in response to inflammatory conditions suggesting its role in modulating immune responses.
Biological function summary

TIM-3 functions as a checkpoint inhibitor impacting immune cell activity. It is not part of a larger physical complex but it modulates immune responses by interacting with its ligands such as Galectin-9 phosphatidylserine and CEACAM1. TIM-3 involvement in downregulating Th1 cell responses shows its necessary role in maintaining immune homeostasis. The protein also acts in regulating tolerance mechanisms and preventing autoimmunity.

Pathways

TIM-3 participation is seen in the immune checkpoint and T cell exhaustion pathways. TIM-3 signaling results in T cell inhibition affecting the PD-1 pathway as well. It shares a relationship with proteins like LAG-3 and PD-1 which are key to immune inhibitory signaling. These interactions depict TIM-3's role in immune tolerance during chronic infections and malignancies.

TIM-3 association with cancer and chronic infections provides insight into therapeutic implications. In cancer TIM-3 contributes to immune evasion often co-expressed with PD-1 leading to T cell exhaustion. In autoimmune diseases TIM-3 modulation may affect disease progression by influencing immune tolerance. Understanding TIM-3's role in these contexts aids in developing targeted therapies such as anti-TIM-3 antibodies to enhance immune responses in cancer while promoting tolerance in autoimmunity.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Cell surface receptor implicated in modulating innate and adaptive immune responses. Generally accepted to have an inhibiting function. Reports on stimulating functions suggest that the activity may be influenced by the cellular context and/or the respective ligand (PubMed : 24825777). Regulates macrophage activation (PubMed : 11823861). Inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance (PubMed : 14556005). In CD8+ cells attenuates TCR-induced signaling, specifically by blocking NF-kappaB and NFAT promoter activities resulting in the loss of IL-2 secretion. The function may implicate its association with LCK proposed to impair phosphorylation of TCR subunits, and/or LGALS9-dependent recruitment of PTPRC to the immunological synapse (PubMed : 24337741, PubMed : 26492563). In contrast, shown to activate TCR-induced signaling in T-cells probably implicating ZAP70, LCP2, LCK and FYN (By similarity). Expressed on Treg cells can inhibit Th17 cell responses (PubMed : 24838857). Receptor for LGALS9 (PubMed : 16286920, PubMed : 24337741). Binding to LGALS9 is believed to result in suppression of T-cell responses; the resulting apoptosis of antigen-specific cells may implicate HAVCR2 phosphorylation and disruption of its association with BAG6. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens. Expressed on Th1 cells interacts with LGALS9 expressed on Mycobacterium tuberculosis-infected macrophages to stimulate antibactericidal activity including IL-1 beta secretion and to restrict intracellular bacterial growth (By similarity). However, the function as receptor for LGALS9 has been challenged (PubMed : 23555261). Also reported to enhance CD8+ T-cell responses to an acute infection such as by Listeria monocytogenes (By similarity). Receptor for phosphatidylserine (PtSer); PtSer-binding is calcium-dependent. May recognize PtSer on apoptotic cells leading to their phagocytosis. Mediates the engulfment of apoptotic cells by dendritic cells. Expressed on T-cells, promotes conjugation but not engulfment of apoptotic cells. Expressed on dendritic cells (DCs) positively regulates innate immune response and in synergy with Toll-like receptors promotes secretion of TNF. In tumor-imfiltrating DCs suppresses nucleic acid-mediated innate immune repsonse by interaction with HMGB1 and interfering with nucleic acid-sensing and trafficking of nucleid acids to endosomes (By similarity). Expressed on natural killer (NK) cells acts as a coreceptor to enhance IFN-gamma production in response to LGALS9 (PubMed : 22323453). In contrast, shown to suppress NK cell-mediated cytotoxicity (PubMed : 22383801). Negatively regulates NK cell function in LPS-induced endotoxic shock (By similarity).
See full target information HAVCR2

Publications (43)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in immunology 16:1524930 PubMed40207224

2025

Exploring the possible mechanism of low-dose naloxone exposure improving the immune microenvironment of gastric cancer tumors.

Applications

Unspecified application

Species

Unspecified reactive species

Xiangzhen Min,Yan Ma,Mingyue Lv,Xiaoxi Li,Renjun Lv,Xiaoyong Zhao,Yufang Leng

Communications biology 7:1090 PubMed39237613

2024

TIM-3 on myeloid cells promotes pulmonary inflammation through increased production of galectin-3.

Applications

Unspecified application

Species

Unspecified reactive species

Ki Sun Kim,Chanju Lee,Hyung-Seok Kim,Su Jeong Gu,Hee Jung Yoon,Su Bin Won,Ho Lee,Yong Sun Lee,Sang Soo Kim,Lawrence P Kane,Eun Jung Park

Biomedicines 12: PubMed38672108

2024

The Expression Patterns of Immune Checkpoint Molecules in Colorectal Cancer: An Analysis Based on Microsatellite Status.

Applications

Unspecified application

Species

Unspecified reactive species

Sanghyun An,Wanlu Li,Hyejin Do,Hye Youn Kwon,Bora Kim,Kwangmin Kim,Youngwan Kim,Mee-Yon Cho

Cell death discovery 9:218 PubMed37393392

2023

Tim-3 protects against cisplatin nephrotoxicity by inhibiting NF-κB-mediated inflammation.

Applications

Unspecified application

Species

Unspecified reactive species

Peiyao Li,Xuemiao Li,Wenbin Wu,Mengjia Hou,Guanyi Yin,Zhonghang Wang,Ziyu Du,Yuanfang Ma,Qiang Lou,Yinxiang Wei

Journal of thoracic disease 15:1433-1444 PubMed37065598

2023

Increased TIM-3 expression in tumor-associated macrophages predicts a poorer prognosis in non-small cell lung cancer: a retrospective cohort study.

Applications

Unspecified application

Species

Unspecified reactive species

Chi Zhang,Liyun Xu,Yongbin Ma,Yanyan Huang,Lu Zhou,Hanbo Le,Zhijun Chen

Cancers 15: PubMed36672332

2023

TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Sofia Valente,Catarina Nascimento,Andreia Gameiro,João Ferreira,Jorge Correia,Fernando Ferreira

Cancers 14: PubMed36358805

2022

Use of High-Plex Data Reveals Novel Insights into the Tumour Microenvironment of Clear Cell Renal Cell Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Raffaele De Filippis,Georg Wölflein,In Hwa Um,Peter D Caie,Sarah Warren,Andrew White,Elizabeth Suen,Emily To,Ognjen Arandjelović,David J Harrison

International journal of immunopathology and pharmacology 35:20587384211061051 PubMed34930041

2021

Splenic CD4 and CD8 T-cells highly expressed PD-1 and Tim-3 in cirrhotic patients with HCV infection and portal hypertension.

Applications

Unspecified application

Species

Unspecified reactive species

Na Huang,Rui Zhou,Haiyan Chen,Shu Zhang,Jun Li,Wei Wei,Jin Sun,Song Ren,Baohua Li,Hong Deng,Jun Yang,Fanpu Ji,Zongfang Li

Translational oncology 15:101306 PubMed34883446

2021

CD169-positive macrophages enhance abscopal effect of radiofrequency ablation therapy in liver cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaojia Song,Na Li,Yuan Liu,Zehua Wang,Tixiao Wang,Siyu Tan,Chunyang Li,Chunhong Qiu,Lifen Gao,Kenichi Asano,Masato Tanaka,Xiaohong Liang,Xinyong Liu,Chunhong Ma

Oncoimmunology 10:2003956 PubMed34804639

2021

BDNF expression in GISTs predicts poor prognosis when associated with PD-L1 positive tumor-infiltrating lymphocytes.

Applications

Unspecified application

Species

Unspecified reactive species

Guang-Ang Tian,Wen-Ting Xu,Yue Sun,Jin Wang,Qing Ke,Meng-Jiao Yuan,Jin-Jin Wang,Chun Zhuang,Qian Gong
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com